Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 21, 2017
Event: Entry into a Material Definitive Agreement (Stock Purchase Agreement) with V-Sciences Investments Pte Ltd ("Temasek").
Key Financial Metrics and Transaction Details
This filing reports a private placement transaction rather than standard operating financial results (revenue, profit, or cash flow for a period are not provided in this document).
- Total Potential Proceeds: Up to approximately $150 million.
- Initial Closing Proceeds: Approximately $75 million.
- Initial Shares Issued: 6,556,116 shares of common stock.
- Price Per Share: $11.44 (97% of the average of the 10-Day VWAP and the August 18 closing bid price).
- Expected Initial Closing Date: August 24, 2017.
Material Changes and Transaction Structure
The Company entered into a Stock Purchase Agreement to sell shares to Temasek. The transaction is structured in two potential tranches:
- Initial Tranche: Immediate sale of 6,556,116 shares for $75 million.
- Contingent Second Tranche: Up to an additional $75 million in proceeds. This is contingent upon the Company receiving marketing approval from the U.S. Food and Drug Administration (FDA) for its pegfilgrastim CHS-1701 biosimilar product candidate. If approved, Temasek will use commercially reasonable efforts to purchase additional shares, subject to market pricing and closing conditions.
The Company also entered into a Registration Rights Agreement, agreeing to file a registration statement within 40 days of each closing and use commercially reasonable efforts to have it declared effective within 100 days.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Company is seeking capital to support its operations, specifically tied to the regulatory milestone of its CHS-1701 biosimilar candidate.
Risks and Contingencies:
- Regulatory Risk: The second tranche of funding ($75 million) is strictly conditional on FDA marketing approval for CHS-1701.
- Market Pricing Risk: The second tranche is subject to agreement on market pricing at the time of the potential future closing.
- Securities Law: The securities sold are exempt from registration under Section 4(a)(2) of the Securities Act and Regulation D; they are not registered and may not be offered or sold in the U.S. absent registration or an applicable exemption.
Key Facts for Investor Verification
- Verify the status of the initial closing scheduled for August 24, 2017, and the receipt of the $75 million proceeds.
- Monitor FDA regulatory updates regarding the CHS-1701 pegfilgrastim biosimilar candidate, as this triggers the potential for an additional $75 million investment.
- Review the filed Registration Rights Agreement (Exhibit 4.1) for specific terms regarding piggyback rights and indemnification.
- Confirm the dilution impact of the 6,556,116 shares issued in the initial tranche on existing shareholders.